Related Experiment Video

Updated: May 17, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting insulin and insulin-like growth factor signaling in breast cancer

Yuzhe Yang1, Douglas Yee

  • 1Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.

Journal of Mammary Gland Biology and Neoplasia
|October 12, 2012
PubMed

Insights

Targeting insulin and insulin-like growth factor (IGF) signaling shows promise in preclinical breast cancer models. However, clinical trials have yielded limited success, necessitating further research into complex pathways and combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Insulin and insulin-like growth factor (IGF) signaling pathways are crucial in breast cancer development and progression.
  • Preclinical models suggest that disrupting these pathways can inhibit tumor growth.

Purpose of the Study:

  • To review current strategies targeting the IGF/insulin system in breast cancer.
  • To discuss reasons for the limited success of existing therapies in clinical trials.
  • To explore future research directions and potential combination therapies.

Main Methods:

  • Literature review of preclinical and clinical studies on IGF/insulin signaling in breast cancer.
  • Analysis of factors contributing to therapeutic success or failure.
  • Exploration of interactions with other signaling pathways like ERα and EGFR.

Main Results:

  • While preclinical data is promising, clinical trials, including Phase III studies, have not demonstrated significant benefits of blocking IGF signaling with conventional treatments.
  • Combination therapies involving anti-IGF/insulin agents and hormone therapy have also shown limited efficacy.
  • The complexity of the IGF/insulin pathway and its interactions with other signaling pathways may explain the translational gap.

Conclusions:

  • There is a critical need for a deeper understanding of the IGF/insulin signaling network in breast cancer.
  • Development of predictive biomarkers and optimized inhibitory strategies are essential for improving clinical outcomes.
  • Investigating the interplay between IGF/insulin, ERα, and EGFR pathways may reveal novel combination therapy concepts.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...